Danaher Corporation $DHR Shares Purchased by Ethic Inc.

Key Points

• Ethic Inc. increased its stake in Danaher Corporation by 7.5%, owning a total of 65,613 shares valued at approximately $13.04 million as of the latest SEC filing.
• Research analysts have a consensus rating of "Moderate Buy" for Danaher, with an average price target of $246.00, reflecting positive sentiment and growth expectations.
• Danaher recently declared a quarterly dividend of $0.32, equivalent to a 0.6% dividend yield, highlighting the company’s commitment to returning value to shareholders.

Ethic Inc. grew its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 7.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 65,613 shares of the conglomerate's stock after purchasing an additional 4,552 shares during the quarter. Ethic Inc.'s holdings in Danaher were worth $13,044,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of DHR. Vanguard Group Inc. raised its holdings in shares of Danaher by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock worth $12,296,123,000 after purchasing an additional 230,966 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Danaher by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock worth $4,016,404,000 after purchasing an additional 612,154 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Danaher by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after buying an additional 194,466 shares in the last quarter. Invesco Ltd. grew its position in Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after purchasing an additional 1,450,703 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Danaher by 4.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate's stock valued at $867,168,000 after purchasing an additional 163,332 shares during the period. Institutional investors own 79.05% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Robert W. Baird lifted their price target on Danaher from $229.00 to $236.00 and gave the company an "outperform" rating in a report on Wednesday, October 15th. Evercore ISI increased their price target on shares of Danaher from $226.00 to $245.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 7th. Bank of America lowered their price objective on shares of Danaher from $230.00 to $220.00 and set a "buy" rating on the stock in a research report on Monday, September 22nd. Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Finally, Guggenheim reissued a "buy" rating and set a $250.00 price objective on shares of Danaher in a research report on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $246.00.

Insider Activity at Danaher

In related news, Director Teri List sold 2,778 shares of the company's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 11.20% of the stock is currently owned by company insiders.

Danaher Stock Down 0.9%

NYSE DHR opened at $218.81 on Wednesday. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $260.88. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The firm has a 50-day simple moving average of $202.07 and a 200 day simple moving average of $197.59. The stock has a market cap of $156.68 billion, a PE ratio of 47.04, a PEG ratio of 3.01 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, October 21st. The conglomerate reported $1.89 EPS for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter in the previous year, the firm earned $1.71 EPS. Danaher's quarterly revenue was up 4.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, research analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio (DPR) is currently 27.23%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.